Actinomycin D (Dactinomycin)
别名: Act D, RASP-101 中文名称：放线菌素D, 更生霉素
此产品请避光密封保存。
Actinomycin D (Dactinomycin, Act D, RASP-101)是一种从链霉菌属的土壤细菌中分离出来的重要的多肽抗生素。Actinomycin D (Dactinomycin) 可抑制 DNA repair，并使 cell cycle 停滞在G1期，其IC50值分别为0.42 μM和0.4 nM。Actinomycin D (Dactinomycin) 是 autophagy 的激活剂，可在高危慢性淋巴细胞性白血病中诱导p53依赖性细胞的死亡并延长生存期。此产品为危化品（急性毒性/易燃/皮肤腐蚀），请在穿戴防护面罩、防护手套和防护服后使用。 已取得危险化学品经营许可
Actinomycin D (Dactinomycin) Chemical Structure
CAS: 50-76-0
产品质控
批次：
纯度：
99.74%
99.74
Actinomycin D (Dactinomycin)相关产品
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| NCI-H157 | Apoptosis assay | 10 uM | 5 hrs | Induction of apoptosis in human NCI-H157 cells assessed as live cell level at 10 uM incubated for 5 hrs in serum-free medium by annexin V/propidium iodide staining by flow cytometry | 22863528 |
| HeLa | Cytotoxicity assay | 1 uM | 18 hrs | Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 1 uM after 18 hrs by inverse MTT assay | 25028062 |
| A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay, EC50 = 0.000201 μM. | 27736087 | |
| PC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay, EC50 = 0.000276 μM. | 27736087 | |
| L1210 | Function assay | 3 hrs | Inhibition of RNA synthesis in mouse L1210 cells assessed as [3H]-uridine incorporation preincubated for 3 hrs before [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis, ED50 = 0.009 μM. | 330857 | |
| L1210 | Function assay | 3 hrs | Inhibition of DNA synthesis in mouse L1210 cells assessed as [3H]-thymidine incorporation preincubated for 3 hrs before [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis, ED50 = 0.4 μM. | 330857 | |
| HMO2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HMO2 cells after 48 hrs by sulforhodamine assay, GI50 = 0.3 μM. | 10757717 | |
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine assay, GI50 = 0.5 μM. | 10757717 | |
| HepG2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine assay, GI50 = 1 μM. | 10757717 | |
| P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay, IC50 = 0.0002 μM. | 2778449 | |
| HT-29 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay, IC50 = 0.223 μM. | 2778449 | |
| Jurkat T | Function assay | 48 hrs | Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC50 = 0.0045 μM. | 11052798 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells in log-phase after 48 hrs by MTT assay, IC50 = 0.001 μM. | 16309323 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against african green monkey Vero cells in log-phase after 48 hrs by MTT assay, IC50 = 0.001 μM. | 16309323 | |
| Hep2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human Hep2 cells in log-phase after 48 hrs by MTT assay, IC50 = 0.006 μM. | 16309323 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells in lag-phase after 48 hrs by MTT assay, IC50 = 0.011 μM. | 16309323 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against african green monkey Vero cells in lag-phase after 48 hrs by MTT assay, IC50 = 0.071 μM. | 16309323 | |
| Hep2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human Hep2 cells in lag-phase after 48 hrs by MTT assay, IC50 = 0.191 μM. | 16309323 | |
| CCRF-CEM | Cytotoxicity assay | 72 hrs | Cytotoxicity against human CCRF-CEM cells after 72 hrs, IC50 = 0.0016 μM. | 18329887 | |
| HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay, IC50 = 0.0004 μM. | 18461997 | |
| HT29 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HT29 cells after 48 hrs by MTT assay, IC50 = 0.0029 μM. | 18461997 | |
| U2OS | Antiproliferative assay | 48 hrs | Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay, IC50 = 0.0032 μM. | 18461997 | |
| HeLa | Function assay | 2 hrs | Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting, IC50 = 0.2624 μM. | 20118940 | |
| HeLa | Function assay | 2 hrs | Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy, IC50 = 0.5197 μM. | 20118940 | |
| NCI-H460 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H460 cells after 72 hrs by MTS reduction assay, IC50 = 0.008 μM. | 20704331 | |
| SF268 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SF268 cells after 72 hrs by MTS reduction assay, IC50 = 0.016 μM. | 20704331 | |
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells after 72 hrs by MTS reduction assay, IC50 = 0.103 μM. | 20704331 | |
| Vero | Cytotoxicity assay | 20 hrs | Cytotoxicity against african green monkey Vero cells after 20 hrs by MTS assay, IC50 = 11 μM. | 21093966 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.0011 μM. | 22705001 | |
| A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.0072 μM. | 22705001 | |
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.024 μM. | 22705001 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.071 μM. | 22705001 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells in lag phase of growth after 48 hrs, IC50 = 0.0011 μM. | 24709561 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells in log phase of growth after 48 hrs, IC50 = 0.0016 μM. | 24709561 | |
| Hep2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human Hep2 cells in log phase of growth after 48 hrs, IC50 = 0.0062 μM. | 24709561 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against African green monkey Vero cells in log phase of growth after 48 hrs, IC50 = 0.01 μM. | 24709561 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against African green monkey Vero cells in lag phase of growth after 48 hrs, IC50 = 0.072 μM. | 24709561 | |
| Hep2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human Hep2 cells in lag phase of growth after 48 hrs, IC50 = 0.17 μM. | 24709561 | |
| HEK293 | Function assay | 30 mins | Inhibition of human DDR2 expressed in HEK293 cells assessed as reduction in collagen-1-induced DDR2 tyrosine phosphorylation pre-incubated for 30 mins by immunoblotting method, IC50 = 9 μM. | 25569119 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.0011 μM. | 28923386 | |
| A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.0072 μM. | 28923386 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.011 μM. | 28923386 | |
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.024 μM. | 28923386 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.071 μM. | 28923386 | |
| A2780 | Cytotoxicity assay | Cytotoxicity against human A2780 cells, Activity = 0.0017 μM. | 16562838 | ||
| L1210 | Function assay | Inhibition of RNA synthesis in mouse L1210 cells by [3H]-uridine incorporation assay, ED50 = 0.015 μM. | 573799 | ||
| L1210 | Function assay | Inhibition of DNA synthesis in mouse L1210 cells by [3H]-thymidine incorporation assay, ED50 = 0.6 μM. | 573799 | ||
| P388 | Function assay | Concentration required for 50% inhibition of incorporation of labeled uridine by P388 cells for the synthesis of RNA (in vitro), ED50 = 0.046 μM. | 6169834 | ||
| P388 | Function assay | Concentration required for 50% inhibition of incorporation of labeled thymidine by p388 cells for synthesis of DNA (in vitro), ED50 = 0.996 μM. | 6169834 | ||
| B104-1-1 | Growth inhibitory assay | Growth inhibitory activity was tested against B104-1-1 cells, GI50 = 0.0007 μM. | 10888331 | ||
| Hep G2 | Cytotoxicity assay | Cytotoxicity against human Hep G2 cells, GI50 = 0.0012 μM. | 16933866 | ||
| HM02 | Cytotoxicity assay | Cytotoxicity against human HM02 cells, GI50 = 0.0016 μM. | 16933866 | ||
| L1210 | Function assay | Inhibition of synthesis of [5-3H]-uridine into RNA in L1210 cells., IC50 = 0.019 μM. | 3397991 | ||
| L1210 | Function assay | Inhibition of synthesis of [methyl-14C] thymidine into DNA, in L1210 cells., IC50 = 0.38 μM. | 3397991 | ||
| Jurkat T | Function assay | Inhibitory concentration against Human Jurkat T cells, IC50 = 0.0045 μM. | 10212121 | ||
| B104-1-1 | Function assay | In vitro binding assay of Shc-derived phosphopeptide to Growth factor receptor bound protein 2 SH2 in B104-1-1 cells was determined, IC50 = 5 μM. | 10888331 | ||
| C8166 | Antitumor assay | Antitumor activity against CD+ human acute T-lymphoblastic leukemia C8166 cells, IC50 = 0.0008 μM. | 12431048 | ||
| CCRF-CEM | Antitumor assay | Antitumor activity against human acute T-lymphoblastic leukemia CCRF-CEM cells, IC50 = 0.001 μM. | 12431048 | ||
| CD4+T | Antitumor assay | Antitumor activity against human CD4+T cells expressing the TAT gene of HTLV-1 MT-4 cells, IC50 = 0.001 μM. | 12431048 | ||
| MOLT-4 | Antitumor assay | Antitumor activity against human acute T-lymphoblastic leukemia MOLT-4 cells, IC50 = 0.001 μM. | 12431048 | ||
| G-361 | Antitumor assay | Antitumor activity against human skin melanoma G-361 cells, IC50 = 0.001 μM. | 12431048 | ||
| MT-4 | Antitumor assay | Antitumor activity against CD+ human acute T-lymphoblastic leukemia MT-4 cells, IC50 = 0.001 μM. | 12431048 | ||
| CCRF-SB | Antitumor assay | Antitumor activity against human acute B-lymphoblastic leukemia CCRF-SB cells, IC50 = 0.002 μM. | 12431048 | ||
| SKMEK-28 | Antitumor assay | Antitumor activity against human skin melanoma SKMEK-28 cells, IC50 = 0.002 μM. | 12431048 | ||
| Raji | Antitumor assay | Antitumor activity against human Burkitt lym phoma Raji cells, IC50 = 0.002 μM. | 12431048 | ||
| 5637 | Antitumor assay | Antitumor activity against human bladder carcinoma 5637 cells, IC50 = 0.003 μM. | 12431048 | ||
| Wil2-NS | Antitumor assay | Anti tumor activity against human splenic B-lympho blastoid Wil2-NS cells, IC50 = 0.003 μM. | 12431048 | ||
| Hep-2 | Antitumor assay | Antitumor activity against larynx carcinoma Hep-2 cells, IC50 = 0.004 μM. | 12431048 | ||
| SK-MES-1 | Antitumor assay | Antitumor activity against human lung squamous carcinoma SK-MES-1 cells, IC50 = 0.004 μM. | 12431048 | ||
| ACHN | Antitumor assay | Antitumor activity against human renal adenocarcinoma ACHN cells, IC50 = 0.005 μM. | 12431048 | ||
| KB | Function assay | Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%, IC50 = 0.005 μM. | 12431048 | ||
| HT-29 | Antitumor assay | Antitumor activity against human colon adenocarcinoma HT-29 cells, IC50 = 0.006 μM. | 12431048 | ||
| MCF-7 | Antitumor assay | Antitumor activity against human breast adenocarcinoma MCF-7 cells, IC50 = 0.006 μM. | 12431048 | ||
| CRL7065 | Antitumor assay | Antitumor activity against human foreskin fibroblasts CRL7065 cells, IC50 = 0.007 μM. | 12431048 | ||
| DU145 | Antitumor assay | Antitumor activity against human prostate carcinoma DU145 cells, IC50 = 0.008 μM. | 12431048 | ||
| Hela | Antitumor assay | Antitumor activity against cervix carcinoma Hela cells cells, IC50 = 0.008 μM. | 12431048 | ||
| HepG2 | Antitumor assay | Antitumor activity against human hepatocellular carcinoma HepG2 cells, IC50 = 0.01 μM. | 12431048 | ||
| C8166 | Antitumor assay | Antitumor activity against CD4+ human acute T-lymphoblastic C8166 leukemia cells., IC50 = 0.00008 μM. | 12431049 | ||
| MT-4 | Antitumor assay | Antitumor activity against CD4+ human acute T-lymphoblastic MT-4 leukemia cells., IC50 = 0.0009 μM. | 12431049 | ||
| G361 | Antitumor assay | Antitumor activity against human skin melanoma G361 cells., IC50 = 0.001 μM. | 12431049 | ||
| MOLT-4 | Antitumor assay | Antitumor activity against human acute T-lymphoblastic MOLT-4 leukemia cells., IC50 = 0.001 μM. | 12431049 | ||
| CCRF-SB | Antitumor assay | Antitumor activity against human acute B-lymphoblastic CCRF-SB leukemia cells., IC50 = 0.001 μM. | 12431049 | ||
| Raji | Antitumor assay | Antitumor activity against human Burkitt lymphoma Raji cells., IC50 = 0.002 μM. | 12431049 | ||
| 5637 | Antitumor assay | Antitumor activity against human bladder carcinoma 5637 cells., IC50 = 0.003 μM. | 12431049 | ||
| CCRF-CEM | Antitumor assay | Antitumor activity against human acute T-lymphoblastic CCRF-CEM leukemia cells., IC50 = 0.003 μM. | 12431049 | ||
| Wil-NS | Antitumor assay | Antitumor activity against human splenic B-lymphoblastoid Wil-NS cells., IC50 = 0.003 μM. | 12431049 | ||
| Hep-2 | Antitumor assay | Antitumor activity against Hep-2 larynx carcinoma cells., IC50 = 0.004 μM. | 12431049 | ||
| ACHN | Antitumor assay | Antitumor activity against human renal adenocarcinoma ACHN cells., IC50 = 0.005 μM. | 12431049 | ||
| MCF-7 | Antitumor assay | Antitumor activity against human breast adenocarcinoma MCF-7 cells., IC50 = 0.006 μM. | 12431049 | ||
| HT-29 | Antitumor assay | Antitumor activity against human colon adenocarcinoma HT-29 cells., IC50 = 0.006 μM. | 12431049 | ||
| HepG-2 | Antitumor assay | Antitumor activity against human hepatocellular carcinoma HepG-2 cells., IC50 = 0.01 μM. | 12431049 | ||
| HeLa | Antitumor assay | Antitumor activity against HeLa cervical carcinoma cells., IC50 = 0.04 μM. | 12431049 | ||
| CCRF-CEM | Cytotoxicity assay | Cytotoxicity in human leukemic CCRF-CEM cells., IC50 = 1.6 μM. | 14667232 | ||
| A2780 | Cytotoxicity assay | Cytotoxicity against human A2780 cells, IC50 = 0.0008 μM. | 15844934 | ||
| A2780 | Cytotoxicity assay | Cytotoxicity against human A2780 cells, IC50 = 0.0008 μM. | 16180816 | ||
| MOLT3 | Cytotoxicity assay | Cytotoxicity against MOLT3 Leukemia cells by MTS assay, IC50 = 1 μM. | 16420056 | ||
| U937 | Cytotoxicity assay | Cytotoxicity against U937 Lymphoma cells by MTS assay, IC50 = 1 μM. | 16420056 | ||
| Vero | Cytotoxicity assay | Cytotoxicity against normal vero kidney cells by MTS assay, IC50 = 11 μM. | 16420056 | ||
| Wil2-NS | Antiproliferative assay | Antiproliferative activity against human Wil2-NS cells by MTT assay, IC50 = 0.003 μM. | 16913700 | ||
| HeLa | Antiproliferative assay | Antiproliferative activity against human HeLa cells by MTT assay, IC50 = 0.04 μM. | 16913700 | ||
| B16 | Growth inhibition assay | In vitro 50% Growth inhibition of sensitive B16 cells., ID50 = 0.003 μM. | 3397991 | ||
| L1210 | Growth inhibition assay | 50% Inhibition of growth of L1210 cells in culture., ID50 = 0.0601 μM. | 3397991 | ||
| P388/ADR | Growth inhibition assay | In vitro 50% Growth inhibition of actinomycin resistant P388/ADR cells, ID50 = 2.5 μM. | 3397991 | ||
| HeLa | Apoptosis assay | Induction of apoptosis in human HeLa cells assessed as DNA fragmentation by agarose gel electrophoresis | 22705001 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | ||
| Daoy | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells | 29435139 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 29435139 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells | 29435139 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Actinomycin D (Dactinomycin, Act D, RASP-101)是一种从链霉菌属的土壤细菌中分离出来的重要的多肽抗生素。Actinomycin D (Dactinomycin) 可抑制 DNA repair，并使 cell cycle 停滞在G1期，其IC50值分别为0.42 μM和0.4 nM。Actinomycin D (Dactinomycin) 是 autophagy 的激活剂，可在高危慢性淋巴细胞性白血病中诱导p53依赖性细胞的死亡并延长生存期。此产品为危化品（急性毒性/易燃/皮肤腐蚀），请在穿戴防护面罩、防护手套和防护服后使用。 | ||||||
|---|---|---|---|---|---|---|---|
| 靶点 |
|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06252285 | Recruiting | RSV Immunisation |
Sanofi Pasteur a Sanofi Company|Sanofi |
February 6 2024 | Phase 3 |
| NCT05858723 | Not yet recruiting | Allergic Contact Dermatitis |
National Allergy Research Center Denmark |
August 2023 | Not Applicable |
化学信息&溶解度
| 分子量 | 1255.42 | 分子式 | C62H86N12O16 |
| CAS号 | 50-76-0 | SDF | -- |
| 储存条件(自收到货起) | 3年 -20°C(避光) 粉状 | ||
|
体外溶解度 |
DMSO : 100 mg/mL ( (79.65 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy Actinomycin D (Dactinomycin) | Actinomycin D (Dactinomycin) supplier | purchase Actinomycin D (Dactinomycin) | Actinomycin D (Dactinomycin) cost | Actinomycin D (Dactinomycin) manufacturer | order Actinomycin D (Dactinomycin) | Actinomycin D (Dactinomycin) distributor
